Overview Dividends

(CORT) Corcept Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2183521028

Hormonemodulator, Korlym, Relacorilant, Dazucorilant, Miricorilant

CORT EPS (Earnings per Share)

EPS Growth (3Y CAGR): -0.62%
EPS Trend (3Y Correlation): 32.0%

CORT Revenue

Revenue Growth (3Y CAGR): 26.56%
Revenue Trend (3Y Correlation): 95.7%

Description: CORT Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing medications for severe endocrine, oncologic, metabolic, and neurologic disorders. The companys lead product, Korlym, is used to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome. Korlym has shown significant revenue growth, contributing substantially to the companys financials.

The companys pipeline includes several promising candidates: relacorilant, which is in Phase III trials for hypercortisolism and platinum-resistant ovarian tumors; dazucorilant, in Phase II trials for amyotrophic lateral sclerosis; and miricorilant, also in Phase IIb trials for metabolic dysfunction-associated steatohepatitis. These candidates target various high-value therapeutic areas, indicating potential for future growth.

From a financial perspective, Corcept Therapeutics has a market capitalization of approximately $7.6 billion, with a forward P/E ratio of 55.25, indicating a relatively high valuation likely due to its growth prospects. The Return on Equity (RoE) stands at 20.46%, suggesting effective use of shareholder capital. Key Performance Indicators (KPIs) to watch include revenue growth from Korlym sales, progression of pipeline candidates through clinical trials, and the companys ability to expand its therapeutic areas.

Analyzing the companys progress requires monitoring its cash position, R&D expenses, and milestones achieved in clinical trials. With a strong pipeline and a marketed product, Corcept Therapeutics is positioned for potential long-term growth, contingent on successful trial outcomes and effective commercialization strategies.

CORT Stock Overview

Market Cap in USD	7,521m
Sub-Industry	Pharmaceuticals
IPO / Inception	2004-04-14

CORT Stock Ratings

Growth Rating	88.5%
Fundamental	78.7%
Dividend Rating	-
Return 12m vs S&P 500	71.4%
Analyst Rating	4.50 of 5

CORT Dividends

Currently no dividends paid

CORT Growth Ratios

Growth Correlation 3m	-15.5%
Growth Correlation 12m	81.3%
Growth Correlation 5y	74.7%
CAGR 5y	42.39%
CAGR/Max DD 3y	0.93
CAGR/Mean DD 3y	1.99
Sharpe Ratio 12m	0.17
Alpha	91.42
Beta	0.726
Volatility	44.40%
Current Volume	664.6k
Average Volume 20d	652.8k
Stop Loss	70.3 (-3.5%)
Signal	-0.22

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (132.5m TTM) > 0 and > 6% of Revenue (6% = 43.0m TTM)

FCFTA 0.22 (>2.0%) and ΔFCFTA 5.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 41.68% (prev 80.77%; Δ -39.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 182.2m > Net Income 132.5m (YES >=105%, WARN >=100%)

Net Debt (-96.1m) to EBITDA (103.8m) ratio: -0.93 <= 3.0 (WARN <= 3.5)

Current Ratio 3.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (120.5m) change vs 12m ago 8.31% (target <= -2.0% for YES)

Gross Margin 98.37% (prev 98.49%; Δ -0.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 94.45% (prev 79.72%; Δ 14.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' 9.59

(A) 0.37 = (Total Current Assets 443.1m - Total Current Liabilities 144.7m) / Total Assets 801.7m

(B) 0.75 = Retained Earnings (Balance) 599.4m / Total Assets 801.7m

(D) 3.63 = Book Value of Equity 601.9m / Total Liabilities 165.9m

Total Rating: 9.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 78.71

1. Piotroski 5.50pt = 0.50

2. FCF Yield 2.50% = 1.25

3. FCF Margin 25.18% = 6.29

4. Debt/Equity 0.04 = 2.50

5. Debt/Ebitda 0.21 = 2.46

6. ROIC - WACC 4.81% = 6.02

7. RoE 20.10% = 1.67

8. Rev. Trend 95.66% = 4.78

9. Rev. CAGR 26.56% = 2.50

10. EPS Trend 32.02% = 0.80

11. EPS CAGR -0.62% = -0.08

What is the price of CORT shares?

As of September 14, 2025, the stock is trading at USD 72.87 with a total of 664,620 shares traded.
Over the past week, the price has changed by +5.06%, over one month by -0.98%, over three months by +2.37% and over the past year by +104.06%.

Is Corcept Therapeutics a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Corcept Therapeutics (NASDAQ:CORT) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 78.71 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CORT is around 87.01 USD . This means that CORT is currently undervalued and has a potential upside of +19.4% (Margin of Safety).

Is CORT a buy, sell or hold?

Corcept Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CORT.

Strong Buy: 2
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CORT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	134.5	84.6%
Analysts Target Price	134.5	84.6%
ValueRay Target Price	97.2	33.4%

Last update: 2025-09-03 08:59

CORT Fundamental Data Overview

Market Cap USD = 7.52b (7.52b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 342.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 63.7321
P/E Forward = 20.9205
P/S = 10.5036
P/B = 11.83
P/EG = 0.61
Beta = 0.196
Revenue TTM = 716.1m USD
EBIT TTM = 102.0m USD
EBITDA TTM = 103.8m USD
Long Term Debt = 21.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (Calculated: Short Term 1.02m + Long Term 21.3m)
Net Debt = -96.1m USD (from netDebt column, last quarter)
Enterprise Value = 7.20b USD (7.52b + Debt 22.3m - CCE 342.2m)
Interest Coverage Ratio = unknown (Ebit TTM 102.0m / Interest Expense TTM 0.0)
FCF Yield = 2.50% (FCF TTM 180.3m / Enterprise Value 7.20b)
FCF Margin = 25.18% (FCF TTM 180.3m / Revenue TTM 716.1m)
Net Margin = 18.51% (Net Income TTM 132.5m / Revenue TTM 716.1m)
Gross Margin = 98.37% ((Revenue TTM 716.1m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Tobins Q-Ratio = 11.97 (Enterprise Value 7.20b / Book Value Of Equity 601.9m)
Interest Expense / Debt = 16.07% (Interest Expense 3.58m / Debt 22.3m)
Taxrate = 12.56% (20.3m / 161.5m)
NOPAT = 89.1m (EBIT 102.0m * (1 - 12.56%))
Current Ratio = 3.06 (Total Current Assets 443.1m / Total Current Liabilities 144.7m)
Debt / Equity = 0.04 (Debt 22.3m / last Quarter total Stockholder Equity 635.8m)
Debt / EBITDA = 0.21 (Net Debt -96.1m / EBITDA 103.8m)
Debt / FCF = 0.12 (Debt 22.3m / FCF TTM 180.3m)
Total Stockholder Equity = 659.4m (last 4 quarters mean)
RoA = 16.53% (Net Income 132.5m, Total Assets 801.7m )
RoE = 20.10% (Net Income TTM 132.5m / Total Stockholder Equity 659.4m)
RoCE = 14.98% (Ebit 102.0m / (Equity 659.4m + L.T.Debt 21.3m))
RoIC = 13.52% (NOPAT 89.1m / Invested Capital 659.4m)
WACC = 8.71% (E(7.52b)/V(7.54b) * Re(8.69%)) + (D(22.3m)/V(7.54b) * Rd(16.07%) * (1-Tc(0.13)))
Shares Correlation 3-Years: 27.27 | Cagr: 0.30%
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.92% ; FCFE base≈157.5m ; Y1≈157.1m ; Y5≈165.8m
Fair Price DCF = 24.73 (DCF Value 2.61b / Shares Outstanding 105.4m; 5y FCF grow -0.90% → 3.0% )
Revenue Correlation: 95.66 | Revenue CAGR: 26.56%
Rev Growth-of-Growth: -5.80
EPS Correlation: 32.02 | EPS CAGR: -0.62%
EPS Growth-of-Growth: -35.59

Additional Sources for CORT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle